Physician profile
John G Williams
NPI 1417907973
$4,108.74
in general payments reported to CMS, 2019-2025
21 companies · $1,716 in 2025
The $1,716 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $195 · 2021: $398 · 2022: $187 · 2023: $294 · 2024: $1,063 · 2025: $1,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,078.50 | 2019-2025 | |
| Alcon Vision LLC | $416.19 | 2019-2025 | Clareon, Luxor, Unity |
| Allergan, INC. | $245.61 | 2019-2022 | |
| Dompe US, INC. | $218.25 | 2021-2025 | Oxervate |
| Abbvie INC. | $162.24 | 2023-2025 | Vuity, Alphagan P, Lumigan |
| Amgen INC. | $158.73 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $155.92 | 2023-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Oyster Point Pharma, INC. | $109.70 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $91.02 | 2019 | |
| Rayner Intraocular Lenses Limited | $79.14 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $72.55 | 2020-2022 | |
| Rxsight INC | $71.02 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $46.93 | 2023-2024 | Xiidra, Miebo |
| Ocular Therapeutix, INC. | $37.47 | 2024 | Dextenza |
| Omeros Corporation | $36.50 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $31.23 | 2019-2020 | |
| Shire North American Group INC | $27.93 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.05 | 2020 | |
| Glaukos Corporation | $18.70 | 2019 | |
| Eyepoint US, INC. | $13.94 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.